TOKYO, Jun 18 (Pulse News Wire) – StemRIM Inc. (4599.T) reported on June 18 that it would recognize additional non-operating income of ¥60.0 million from a government grant received during its fiscal fourth quarter ending July 31, 2026.
The grant is part of the Ministry of Health, Labour and Welfare’s “Regenerative Medicine and Gene Therapy Industrialization Promotion Project” funded by the Japan Agency for Medical Research and Development (AMED). This grant covers research and development costs up to two-thirds and allows for potential receipt of up to ¥179 million through fiscal year 2028. In the current fiscal year, the company has confirmed grants totaling ¥12.1 million for fiscal 2025 and ¥60.0 million for fiscal 2026, which have already been recorded as non-operating income.
The project focuses on developing curative gene therapy technology for severe nutritional epidermolysis bullosa, a debilitating genetic skin disorder without existing effective treatments. The treatment involves extracting mesenchymal stem cells from patients' skin, modifying them with lentiviral vectors to introduce VII-type collagen genes, and reintroducing them to restore long-term collagen supply. This innovative approach utilizing patients’ own cells holds promise for sustained therapeutic effects and could offer a breakthrough treatment option for those suffering from this condition, significantly improving their quality of life.
The grant funding supports the manufacturing infrastructure established under AMED Step 1 and leverages advice from the Pharmaceuticals and Medical Devices Agency (PMDA) to expedite clinical trials and practical application.
🟡 Confidence: Standard AI-translated content.